As previously announced in June, Synthetic Blood International has changed its name to Oxygen Biotherapeutics, Inc. effective today. The company will continue to trade on the Over-the-Counter Bulletin Board but with a new symbol. Starting with the opening of trading today, the company’s new trading symbol will be OXBO.
The company’s focus will continue to be the same. Oxygen Biotherapeutics is dedicated to transforming patient care by developing advanced, oxygen-based therapies using Oxycyte®, the company’s perfluorocarbon (PFC) therapeutic oxygen carrier, and other solutions. The company believes Oxycyte has the potential for use in multiple indications, including traumatic brain injury, sickle-cell pain crisis, decompression sickness, stroke, heart attack, and wound treatment. Based on the number of incidences and need for treatment, the company estimates that the worldwide market potential for all biotherapeutic uses of oxygen therapies could be up to the double-digit millions.
Commenting on the new corporate name, chairman and CEO Chris J. Stern, DBA stated, “Our new name better reflects the broader scope of our development activities. We have several exciting bio-therapeutic applications for Oxycyte®, yet none of them is synthetic blood. What we’re doing is developing advanced oxygen-based therapies using Oxycyte including traumatic brain injury, sickle cell pain crisis, wound treatment, organ transport, heart attack, stroke, and, as a long shot, spinal cord injury.” .
In regards to information related to the company and communications, the company will be utilizing the new company’s website at www.oxybiomed.com
Let us hear your thoughts below:
